Status:

COMPLETED

Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention

Lead Sponsor:

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

Collaborating Sponsors:

Germans Trias i Pujol Hospital

Department of Health, Generalitat de Catalunya

Conditions:

COVID-19

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This study is a research project to evaluate the efficacy of hydroxychloroquine for post-exposure prophylaxis and early treatment of Covid-19. The intervention entails administering prophylactic hydro...

Detailed Description

Hydroxychloroquine (HCQ) is a drug that has been extensively used for the prevention of malaria. HCQ showed excellent in vitro results and strong antiviral effects on SARS-CoV-2 infection of primate c...

Eligibility Criteria

Inclusion

  • Study 1:
  • Inclusion Criteria for a contact:
  • Asymptomatic individuals exposed to a PCR confirmed COVID19 case within 7 days as either a healthcare worker or household contact
  • Aged ≥18 years male or female;
  • In women of childbearing potential, negative pregnancy test and commitment to use contraceptive method throughout the study.
  • Willing to take study medication;
  • Willing to comply with all study procedures;
  • Able to provide oral, informed consent and/or assent.
  • Exclusion Criteria for a contact:
  • With known history of cardiac arrhythmia (or QT prolongation syndrome);
  • Unable to take drugs by mouth;
  • With significantly abnormal liver function (Child Pugh C)
  • Need of dialysis treatment, or GFR≤30 mL/min/1.73 m2;
  • Participants with psoriasis, myasthenia, haematopoietic and retinal diseases,CNS-related hearing loss or glucose-6-phosphate dehydrogenase deficit;
  • Persons already treated with any of the study drugs during the last 30 days;
  • Pregnant or lactating women;
  • Any contraindications as per the Data Sheet of Hydroxychloroquine.
  • Study 2:
  • Inclusion Criteria for a case:
  • Patients who meet the requirements of the New Coronavirus Infection Diagnosis (Acute \<5 days respiratory infection symptoms, or fever alone, or acute cough alone and positive PCR)
  • Aged ≥18 years male or female;
  • In women of childbearing potential, negative pregnancy test and commitment to use contraceptive method throughout the study.
  • Willing to take study medication
  • Willing to comply with all study procedures, including repeat nasal swab at day 3
  • Able to provide oral and written informed consent
  • Exclusion Criteria for a case:
  • Hospital admission
  • Serious condition meeting one of the following: (1) respiratory distress with respiratory rate \>=30 breaths/min; (2) oxygen saturation\<=93% on quiet status; (3) Arterial partial pressure of oxygen (PaO2)/oxygen concentration\<=300mmHg;
  • Critically ill patients meeting one of the following: (1) Experience respiratory failure and need to receive mechanical ventilation; (2) Experience shock; (3) Complicated with other organs failure and need intensive care and therapy in ICU;
  • Participants under treatment with medications likely to interfere with experimental drugs
  • Unable to take drugs by mouth;
  • With significantly abnormal liver function (Child Pugh C)
  • Need of dialysis treatment, or GFR≤30 mL/min/1.73 m2;
  • Participants with psoriasis, myasthenia, haematopoietic and retinal diseases,CNS-related hearing loss or glucose-6-phosphate dehydrogenase deficit
  • Participants with severe neurological and mental illness;
  • Pregnant or lactating women;
  • Inability to consent and/or comply with study protocol;
  • Individuals with known hypersensitivity to the study drugs.
  • Persons already treated with any of the study drugs during the last 30 days.
  • Any contraindications as per the Data Sheet of Hydroxychloroquine.

Exclusion

    Key Trial Info

    Start Date :

    March 18 2020

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    June 15 2020

    Estimated Enrollment :

    2300 Patients enrolled

    Trial Details

    Trial ID

    NCT04304053

    Start Date

    March 18 2020

    End Date

    June 15 2020

    Last Update

    June 30 2020

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Departament de Salut

    Barcelona, Spain